Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.
No abstract available

Keywords: dexamethasone; lenalidomide; multiple myeloma; pembrolizumab; relapsed/refractory.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Lenalidomide / pharmacology
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Dexamethasone
  • pembrolizumab
  • Lenalidomide